<?xml version='1.0' encoding='utf-8'?>
<document id="32223485"><sentence text="In vitro inhibitory effects of cepharanthine on human liver cytochrome P450 enzymes."><entity charOffset="31-44" id="DDI-PubMed.32223485.s1.e0" text="cepharanthine" /></sentence><sentence text="Context: Cepharanthine (CEP) extracted from the roots of Stephania cepharantha Hayata (Menispermaceae), has a range of therapeutic potential in clinical conditions"><entity charOffset="9-22" id="DDI-PubMed.32223485.s2.e0" text="Cepharanthine" /><entity charOffset="24-27" id="DDI-PubMed.32223485.s2.e1" text="CEP" /><pair ddi="false" e1="DDI-PubMed.32223485.s2.e0" e2="DDI-PubMed.32223485.s2.e0" /><pair ddi="false" e1="DDI-PubMed.32223485.s2.e0" e2="DDI-PubMed.32223485.s2.e1" /></sentence><sentence text=" Whether it affects the activity of human liver cytochrome P450 (CYP) enzymes remains unclear" /><sentence text="Materials and methods: The effects of CEP (100 μM) on eight human liver CYP isoforms (i"><entity charOffset="38-40" id="DDI-PubMed.32223485.s4.e0" text="CEP" /></sentence><sentence text="e" /><sentence text=", 1A2, 3A4, 2A6, 2E1, 2D6, 2C9, 2C19 and 2C8) were investigated in vitro using human liver microsomes (HLMs) with specific probe actions and probe substrates" /><sentence text=" In addition, the enzyme kinetic parameters were calculated" /><sentence text="Results: The results showed that the activity of CYP3A4, CYP2E1 and CYP2C9 was inhibited by CEP, with IC50 values of 16"><entity charOffset="92-94" id="DDI-PubMed.32223485.s8.e0" text="CEP" /></sentence><sentence text="29, 25" /><sentence text="62 and 24" /><sentence text="57 μM, respectively, but other CYP isoforms were not affected" /><sentence text=" Enzyme kinetic studies showed that CEP was not only a non-competitive inhibitor of CYP3A4 but also a competitive inhibitor of CYP2E1 and CYP2C9, with Ki values of 8"><entity charOffset="36-38" id="DDI-PubMed.32223485.s12.e0" text="CEP" /></sentence><sentence text="12, 11" /><sentence text="78 and 13" /><sentence text="06 μM, respectively" /><sentence text=" Additionally, CEP is a time-dependent inhibitor for CYP3A4 with KI/Kinact value of 10"><entity charOffset="15-17" id="DDI-PubMed.32223485.s16.e0" text="CEP" /></sentence><sentence text="84/0" /><sentence text="058 min/μM" /><sentence text="Discussion and conclusions: The in vitro studies of CEP with CYP isoforms indicate that CEP has the potential to cause pharmacokinetic drug interactions with other co-administered drugs metabolized by CYP3A4, CYP2E1 and CYP2C9"><entity charOffset="52-54" id="DDI-PubMed.32223485.s19.e0" text="CEP" /><entity charOffset="88-90" id="DDI-PubMed.32223485.s19.e1" text="CEP" /><pair ddi="false" e1="DDI-PubMed.32223485.s19.e0" e2="DDI-PubMed.32223485.s19.e0" /><pair ddi="false" e1="DDI-PubMed.32223485.s19.e0" e2="DDI-PubMed.32223485.s19.e1" /></sentence><sentence text=" Further clinical studies are needed to evaluate the significance of this interaction" /><sentence text="" /></document>